Natera Inc
Geschlossen
BrancheGesundheitswesen
324.91 -1.57
Übersicht
Veränderung der Aktienkurses
24h
Min
320
Max
330.44
Einkommen | 18M -67M |
|---|---|
Verkäufe | 56M 753M |
EPS | -0.47 |
Gewinnspanne | -8.897 |
Angestellte | 6,135 |
EBITDA | 20M -45M |
Nächstes Ergebnis | 5. Nov. 2026 |
|---|
Marktkapitalisierung | 8.6B 47B |
|---|---|
Vorheriger Eröffnungskurs | 326.48 |
Vorheriger Schlusskurs | 324.91 |
Nachrichtenstimmung
By Acuity
39%
61%
109 / 339 Ranking in Healthcare
Natera Inc Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Ähnliche Nachrichten
Peer-Vergleich
Kursveränderung
Natera Inc Prognose
Stimmung
By Acuity
109 / 339 Ranking in Gesundheitswesen
Nachrichtenstimmung
Bullische Evidenz
Volatilität
Unterdurchschnittlich
Nachrichtenvolumen (RCV)
Unterdurchschnittlich
Finanzen
Vertriebs- und Verwaltungskosten
Betriebsaufwand
Gewinn vor Steuern
Verkäufe
Umsatzkosten
Bruttogewinn aus dem Verkauf
Zinsaufwand für Schulden
EBITDA
Betriebsergebnis
$
Über Natera Inc
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
